Anlotinib for Esophageal Cancer (AFEC)
Sponsor
Anyang Tumor Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT04966611
Collaborator
(none)
200
1
36
5.6
Study Details
Study Description
Brief Summary
The purpose of this study is to observe and explore the effect of single or combined treatment of arotinib on the survival and prognosis of patients with advanced esophageal cancer in the real world, and to summarize the treatment experience of a wide range of people.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Study Design
Study Type:
Observational
Anticipated Enrollment
:
200 participants
Observational Model:
Other
Time Perspective:
Prospective
Official Title:
A Real World Study on the Effect of Single or Combined Treatment of Anlotinib on Survival and Prognosis of Advanced Esophageal Cancer
Anticipated Study Start Date
:
Jul 15, 2021
Anticipated Primary Completion Date
:
Jul 15, 2023
Anticipated Study Completion Date
:
Jul 15, 2024
Outcome Measures
Primary Outcome Measures
- OS [From date of admission until the date of death from any cause, assessed up to 24 months]
Overall Survival
Secondary Outcome Measures
- PFS [From date of admission until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months]
Progression Free Survival
Eligibility Criteria
Criteria
Ages Eligible for Study:
N/A
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
Age: ≥ 18 years old, male or female;
-
Patients with esophageal cancer were diagnosed;
-
Patients assessed by doctors to benefit from single or combined treatment of arotinib;
-
Patients volunteered to join the project.
Exclusion Criteria:
None
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Anyang Cancer Hospital | Anyang | China |
Sponsors and Collaborators
- Anyang Tumor Hospital
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Junsheng Wang,
Chief physician,
Anyang Tumor Hospital
ClinicalTrials.gov Identifier:
NCT04966611
Other Study ID Numbers:
- AZLL022020001200116
First Posted:
Jul 19, 2021
Last Update Posted:
Jul 19, 2021
Last Verified:
Jul 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: